Quentin, M.
Arsov, C.
Ullrich, T.
Valentin, B.
Hiester, A.
Blondin, D.
Albers, P.
Antoch, G.
Schimmöller, L.
Article History
Received: 29 January 2019
Revised: 27 April 2019
Accepted: 4 June 2019
First Online: 27 June 2019
Compliance with ethical standards
:
: The scientific guarantor of this publication is Lars Schimmöller.
: The authors of this manuscript declare no relationships with any companies, whose products or services may be related to the subject matter of the article.
: One of the authors has significant statistical expertise.No complex statistical methods were necessary for this paper.
: Written informed consent was obtained from all subjects (patients) in this study.
: Institutional Review Board approval was obtained.
: Some study subjects or cohorts have been previously reported:Some patients in study group A were previously enrolled in a prospective randomised trial assessing the diagnostic efficacy of IB-GB and FUS-GB (ClinicalTrials.gov identifier: NCT02220517; Arsov C, Rabenalt R, Blondin D, et al (2015) Eur Urol).Patients in study group B were previously enrolled in a prospective randomised trial assessing the diagnostic efficacy of IB-GB in comparison with TRUS-GB in biopsy-naïve men with elevated PSA (ClinicalTrials.gov identifier: NCT01553838; Quentin M, Blondin D, Arsov C, et al (2014) J Urol).
: • retrospective• diagnostic or prognostic study• performed at one institution